The Coalition for Excellence in Medication Monitoring (CEMM) – the leading voice of the medication monitoring clinical laboratory industry – has elected Robert Garvey, CEO of Dominion Diagnostics, to serve as its new Chairman.

Dominion Diagnostics is a national medication and substance use monitoring company and a founding member of CEMM.  During Mr. Garvey's tenure as CEO, Dominion has actively pursued innovative solutions to improve patient care.  Prior to joining Dominion, he worked extensively in the health care sector, including senior positions with LabCorp, Quest Diagnostics, and GE Healthcare.

Mr. Garvey looks forward to working collaboratively with CEMM members and policy-makers to promote the importance pain medication monitoring as part of the standard of care for treatment of the millions of Americans who suffer from debilitating chronic pain.  "Pain medication monitoring enhances a physician's clinical judgment and is a critical tool to prevent prescription drug abuse, misuse, and diversion," he emphasized.

About the Coalition for Excellence in Medication Monitoring
The Coalition for Excellence in Medication Monitoring (CEMM) is a coalition of the nation's premier medication monitoring laboratories dedicated to providing high-quality laboratory tests as part of the standard of care for treatment of the millions of Americans who suffer from debilitating chronic pain.  CEMM seeks to educate policy-makers about the value, clinical appropriateness, and cost-effectiveness of medication monitoring laboratory tests.  CEMM also is working to ensure that physicians, health care professionals and patients have the best available clinical data to make informed decisions about pain medication utilization and compliance.